Cargando…
Mucopolysaccharidosis type VI on enzyme replacement therapy since infancy: Six years follow-up of four children()
Clinical and biochemical improvements are reported on Mucopolysaccharidosis type VI (MPS VI) patients on Enzyme Replacement Therapy (ERT) with rhASB (galsulfase, Naglazyme®), and preclinical and clinical studies have shown clinical benefits of early initiation. We report four unrelated MPS VI childr...
Autores principales: | Horovitz, Dafne D.G., Acosta, Angelina Xavier, de Rosso Giuliani, Liane, Ribeiro, Erlane Marques |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471404/ https://www.ncbi.nlm.nih.gov/pubmed/28649537 http://dx.doi.org/10.1016/j.ymgmr.2015.09.002 |
Ejemplares similares
-
Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment
por: Giugliani, Roberto, et al.
Publicado: (2010) -
Enzyme replacement therapy for Mucopolysaccharidosis Type I among patients followed within the MPS Brazil Network
por: Dornelles, Alícia Dorneles, et al.
Publicado: (2014) -
Mucopolysaccharidosis VI
por: Valayannopoulos, Vassili, et al.
Publicado: (2010) -
Enzyme replacement therapy interruption in mucopolysaccharidosis type IVA patients and its impact in different clinical outcomes
por: Politei, Juan, et al.
Publicado: (2021) -
Mucopolysaccharidosis Type I
por: Kubaski, Francyne, et al.
Publicado: (2020)